These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38566091)

  • 21. Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy-naive men based on multi-institutional analysis.
    Ge Q; Zhang S; Xu H; Zhang J; Fan Z; Li W; Shen D; Xiao J; Wei Z
    Cancer Med; 2023 Dec; 12(24):21820-21829. PubMed ID: 38014481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive prostate biopsy standardization system according to quantitative multiparametric MRI and PSA value: P.R.O.S.T score.
    Liang C; Wang Y; Ding L; Bao M; Cheng G; Shao P; Hua L; Liu B; Li J
    World J Urol; 2022 Sep; 40(9):2245-2253. PubMed ID: 35869317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
    Singh S; Rogers H; Kanber B; Clemente J; Pye H; Johnston EW; Parry T; Grey A; Dinneen E; Shaw G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Giganti F; Atkinson D; Moore CM; Whitaker HC; Alexander DC; Panagiotaki E; Punwani S
    Radiology; 2022 Dec; 305(3):623-630. PubMed ID: 35916679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml.
    He BM; Shi ZK; Li HS; Lin HZ; Yang QS; Lu JP; Sun YH; Wang HF
    Ann Surg Oncol; 2020 Apr; 27(4):1284-1295. PubMed ID: 31848822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
    Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
    BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
    Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
    Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-related characteristics predict prostate cancers in men with PI-RADS 4-5 to further optimize the diagnostic performance of MRI.
    Xiang L; Ma S; Xu Y; Jiang L; Guo H; Liu H; Liu Y
    Abdom Radiol (NY); 2023 Dec; 48(12):3766-3773. PubMed ID: 37776336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy.
    Castellani D; Cecchini S; Mazzucchelli R; Soraci L; Di Rosa M; Fabbietti P; Palagonia E; Puccio F; Carnevali F; Paci E; Montironi R; Galosi AB
    Urol Oncol; 2022 Aug; 40(8):379.e1-379.e8. PubMed ID: 35662497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml
    Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Qiu S; Liu ZH; Yang L; Wei Q
    Asian J Androl; 2023; 25(4):492-498. PubMed ID: 36571328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
    Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.
    Wang Y; Wang L; Tang X; Zhang Y; Zhang N; Zhi B; Niu X
    BMC Med Imaging; 2023 Aug; 23(1):106. PubMed ID: 37582697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
    Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
    Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
    Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
    Stavrinides V; Syer T; Hu Y; Giganti F; Freeman A; Karapanagiotis S; Bott SRJ; Brown LC; Burns-Cox N; Dudderidge TJ; Bosaily AE; Frangou E; Ghei M; Henderson A; Hindley RG; Kaplan RS; Oldroyd R; Parker C; Persad R; Rosario DJ; Shergill IS; Echeverria LMC; Norris JM; Winkler M; Barratt D; Kirkham A; Punwani S; Whitaker HC; Ahmed HU; Emberton M;
    Eur Urol; 2021 Jan; 79(1):20-29. PubMed ID: 33051065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
    Boschheidgen M; Albers P; Schlemmer HP; Hellms S; Bonekamp D; Sauter A; Hadaschik B; Krilaviciute A; Radtke JP; Seibold P; Lakes J; Arsov C; Gschwend JE; Herkommer K; Makowski M; Kuczyk MA; Wacker F; Harke N; Debus J; Körber SA; Benner A; Kristiansen G; Giesel FL; Antoch G; Kaaks R; Becker N; Schimmöller L
    Eur Urol; 2024 Feb; 85(2):105-111. PubMed ID: 37863727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
    Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
    Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multivariable stratification of PI-RADS version 2.1 categories for the risk of false-positive target biopsy: Impact on prostate biopsy decisions.
    Girometti R; Giannarini G; De Martino M; Caregnato E; Cereser L; Soligo M; Rozze D; Pizzolitto S; Isola M; Zuiani C
    Eur J Radiol; 2023 Aug; 165():110897. PubMed ID: 37300933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.